Follicular Lymphoma | Tumor

My Traumas Associated With Follicular Lymphoma

November 13th 2024, 6:00pm

Article

I’ve heard that trauma doesn’t make people stronger, and I’ve found that after cancer, I’m not the same person that I was before.

The Need for Self-Advocacy During Cancer

November 5th 2024, 6:00pm

Article

Even if care teams have all of your information on their end, advocating for yourself is still necessary during cancer treatment.

My Unexplained Follicular Lymphoma-Related Weight Loss

October 21st 2024, 5:00pm

Article

Whenever I get sick, I experience a few side effects that usually go away, but unexplained weight loss becomes a problem for me.

Meeting New People and Finding Old Assumptions After Cancer

September 23rd 2024, 5:00pm

Article

Recently, I met a fellow cancer survivor but after talking with her about cancer, I realized she had a different perspective than I did.

Monjuvi May Slow Follicular Lymphoma Progression

August 25th 2024, 5:00pm

Article

Monjuvi, Revlimid and Rituxan improved progression-free survival among adults with relapsed or refractory follicular lymphoma, topline research showed.

‘Fighting Cancer’: My Thoughts on the Phrase

August 23rd 2024, 5:00pm

Article

The militaristic terminology of “fighting a disease” does not sit well with me. After being diagnosed, I wasn’t fighting. I was reacting.

How Cancer Impacts the Perception of Illness

August 8th 2024, 5:00pm

Article

When I started experiencing symptoms of an infection, I was worried that my follicular lymphoma had returned.

My Feeling of Scanxiety But Without the Scan

July 12th 2024, 5:00pm

Article

Having a check-up appointment without receiving any type of scan is good, but also scares me.

Common Platitudes Can Be Hurtful to People With Cancer

July 3rd 2024, 5:00pm

Article

“Everything happens for a reason,” is among some of the unhelpful things you can say to someone with cancer.

FDA Approves Epkinly for Relapsed, Refractory Follicular Lymphoma

June 27th 2024, 12:09am

Article

The Food and Drug Administration approved Epkinly, a bispecific T-cell engager, for certain patients with follicular lymphoma.